Levels of circulating MMCN-151, a degradation product of mimecan, reflect pathological extracellular matrix remodeling in apolipoprotein E knockout mice

Biomarker Insights

Volumn 6, Issue , 2011, Pages 97-106

  Barascuk, N ^a   Vassiliadis, E ^a   Zheng, Q ^b   Wang, Y ^b   Wang, W ^b   Larsen, L ^a   Rasmussen, L M ^c   Karsdal, M A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Nordic Bioscience Beijing   (China)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Atherosclerosis; Biomarker; Extracellular matrix; Matrix metalloproteinases; Mimecan; MMCN 151; Proteoglycans

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; MACROPHAGE ELASTASE; MIMECAN; MONOCLONAL ANTIBODY; PROTEIN MMCN 151; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; IN VITRO STUDY; KNOCKOUT MOUSE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIPID DIET; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL;

MUS;

EID: 80053617871     PISSN: 11772719     EISSN: None     Source Type: Journal    
DOI: 10.4137/BMI.S7777     Document Type: Article

References (33)

1. American Heart Association. Heart Disease and Stroke Statistics-2007 Update. Dallas, Texas: American Heart Association; http://wwwamericanheart.org/downloadable/heart/1166712318459HS_StatsInsideTextpdf. 2007.
2. Kragel AH, Reddy SG, Wittes JT, Roberts WC. Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death. Circulation. December 1989;80(6):1747-56.
3. Wagner WD. Proteoglycan structure and function as related to atherosclerosis. Ann NY Acad Sci. 1985;454:52-68.
4. McCullagh KG, Duance VC, Bishop KA. The distribution of collagen types I, III and V (AB) in normal and atherosclerotic human aorta. J Pathol. January 1980;130(1):45-55.
5. Shekhonin BV, Domogatsky SP, Muzykantov VR, Idelson GL, Rukosuev VS. Distribution of type I, III, IV and V collagen in normal and atherosclerotic human arterial wall: immunomorphological characteristics. Coll Relat Res. September 1985;5(4):355-68.
6. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb. 2003;10(5):267-74.
7. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. August 1994;90(2):775-8.
8. Arroyo LH, Lee RT. Mechanisms of plaque rupture: mechanical and biologic interactions. Cardiovasc Res. February 1999;41(2):369-75.
9. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. January 2007;27(1):15-26.
10. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther. March 2007;5(2):265-82.
11. Kampmann A, Fernandez B, Deindl E, et al. The proteoglycan osteoglycin/ mimecan is correlated with arteriogenesis. Mol Cell Biochem. February 2009;322(1-2):15-23.
12. Tasheva ES, Corpuz LM, Funderburgh JL, Conrad GW. Differential splicing and alternative polyadenylation generate multiple mimecan mRNA transcripts. J Biol Chem. 19 December 1997;272(51):32551-6.
13. Funderburgh JL, Corpuz LM, Roth MR, Funderburgh ML, Tasheva ES, Conrad GW. Mimecan, the 25-kDa corneal keratan sulfate proteoglycan, is a product of the gene producing osteoglycin. J Biol Chem. 31 October 1997;272(44):28089-95.
14. Karsdal MA, Henriksen K, Leeming DJ, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. May 2009;14(3):181-202.
15. Veidal SS, Bay-Jensen AC, Tougas G, Karsdal MA, Vainer B. Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. Dis Markers. 2010;28(1):15-28.
16. Host NB, Jensen LT, Bendixen PM, Jensen SE, Koldkjaer OG, Simonsen EE. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol. 1 November 1995;76(12):869-73.
17. Uemura S, Matsushita H, Li W, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res. 22 June 2001;88(12):1291-8.
18. Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis. June 2003;168(2):263-9.
19. Bellosta S, Baetta R, Canavesi M, et al. Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells. Pharmacol Res. August 2007;56(2):160-7.
20. Lauer-Fields JL, Juska D, Fields GB. Matrix metalloproteinases and collagen catabolism. Biopolymers. 2002;66(1):19-32.
21. Sondergaard BC, Wulf H, Henriksen K, et al. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage. August 2006;14(8):759-68.
22. Karsdal MA, Byrjalsen I, Leeming DJ, Christiansen C. Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation. BMC Musculoskelet Disord. 2008;9:153.
23. Rosenquist C, Fledelius C, Christgau S, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. November 1998;44(11):2281-9.
24. Barascuk N, Veidal SS, Larsen L, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 7 April 2010.
25. Gefter ML, Margulies DH, Scharff MD. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet. March 1977;3(2):231-6.
26. Karsdal MA, Henriksen K, Leeming DJ, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. May 2009;14(3):181-202.
27. Shanahan CM, Cary NR, Osbourn JK, Weissberg PL. Identification of osteoglycin as a component of the vascular matrix. Differential expression by vascular smooth muscle cells during neointima formation and in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. November 1997;17(11):2437-47.
28. Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A. 3 September 1996;93(18):9748-53.
29. Mecham RP, Broekelmann TJ, Fliszar CJ, Shapiro SD, Welgus HG, Senior RM. Elastin degradation by matrix metalloproteinases. Cleavage site specificity and mechanisms of elastolysis. J Biol Chem. 18 July 1997;272(29):18071-6.
30. Luttun A, Lutgens E, Manderveld A, et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation. 23 March 2004;109(11):1408-14.
31. Yamada S, Wang KY, Tanimoto A, et al. Matrix metalloproteinase 12 accelerates the initiation of atherosclerosis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits. Am J Pathol. May 2008;172(5):1419-29.
32. Yamada S, Wang KY, Tanimoto A, et al. Matrix metalloproteinase 12 accelerates the initiation of atherosclerosis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits. Am J Pathol. May 2008;172(5):1419-29.
33. Barascuk N, Vassiliadis E, Larsen L, et al. Development and validation of an enzyme-linked immunosorbent assay for the quantification of a specific MMP-9 mediated degradation fragment of type III collagen-A novel biomarker of atherosclerotic plaque remodeling. Clin Biochem. July 2011;44(10-11):900-6.